Edition:
United Kingdom

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

14.18USD
21 Sep 2018
Change (% chg)

$-0.28 (-1.94%)
Prev Close
$14.46
Open
$14.43
Day's High
$14.58
Day's Low
$13.96
Volume
376,198
Avg. Vol
165,869
52-wk High
$26.05
52-wk Low
$10.25

Chart for

About

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment... (more)

Overall

Beta: 3.18
Market Cap(Mil.): $426.05
Shares Outstanding(Mil.): 32.72
Dividend: --
Yield (%): --

Financials

  GLYC.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.34 -- --
ROI: -38.90 1.79 14.61
ROE: -39.26 3.28 16.33

BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33

* GLYCOMIMETICS INC - AS OF MARCH 31, 2018, GLYCOMIMETICS HAD CASH AND CASH EQUIVALENTS OF $242.6 MILLION AS COMPARED TO $123.9 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

03 May 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.88 +0.90
Novartis AG (NOVN.S) CHF81.88 -0.06
Pfizer Inc. (PFE.N) $44.06 +0.31
Merck & Co., Inc. (MRK.N) $71.10 +0.32
Roche Holding Ltd. (ROG.S) CHF235.15 +0.10
Roche Holding Ltd. (RO.S) CHF235.40 -1.20
Bayer AG (BAYGn.DE) €76.52 +0.70
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates